FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175332015> ?p ?o ?g. }

• W3175332015 endingPage "9275" @default.
• W3175332015 startingPage "9267" @default.
• W3175332015 abstract ": In recent years, immune checkpoint inhibitors (ICIs) have become a standard treatment for patients with advanced lung cancers. With the widespread use of immunotherapy in clinical practice, immune-related adverse events (irAEs) have become increasingly common. This case report details a 72-year-old man with small-cell lung cancer (SCLC) who developed pneumonitis, appendicitis, and biliary obstruction during treatment with toripalimab. The patient was initially diagnosed with limited-stage SCLC in January 2019 and completed 5 sequential cycles of etoposide/cisplatin (EP) and radiotherapy (60 Gy/30 F). The overall response was complete response (CR) after first line treatment. He developed radiation pneumonitis after completion of radiotherapy, which responded well to symptomatic treatment. Due to newly diagnosed bone metastasis, he was administered toripalimab intravenously every 3 weeks and 12 mg anlotinib orally once a day from January 2020. By the third cycle, the patient presented with electrocardiographic abnormalities, gingival swelling and pain, and hoarseness, and consequently, the anlotinib was suspended. After 4 cycles, he developed suppurative appendicitis, which was managed successfully with anti-inflammatory agents. He then presented with shortness of breath on exertion and after a comprehensive examination, he was diagnosed with ICI-related-pneumonitis. After 6 weeks of treatment with methylprednisolone, the shortness of breath was mostly relieved and treatment continued. In June 2020, the patient developed severe vomiting. Computed tomography (CT) indicated biliary obstruction, and at endoscopic retrograde cholangiopancreatography (ERCP) there was edema of the major papilla of the duodenum. The patient’s symptoms were relieved after treatment with gastric acid suppression and antiemetics. Re-examination by magnetic resonance imaging (MRI) showed that the biliary obstruction had been resolved. Although the disease progressed after immunotherapy, no tumor tissue related to the biliary obstruction was detected, and this was therefore classified as an irAE." @default.
• W3175332015 created "2021-07-05" @default.
• W3175332015 creator A5006012404 @default.
• W3175332015 creator A5040027560 @default.
• W3175332015 creator A5052267876 @default.
• W3175332015 creator A5056739581 @default.
• W3175332015 creator A5058579214 @default.
• W3175332015 creator A5065587658 @default.
• W3175332015 creator A5065992804 @default.
• W3175332015 creator A5074498404 @default.
• W3175332015 creator A5077741702 @default.
• W3175332015 creator A5082446850 @default.
• W3175332015 creator A5085659648 @default.
• W3175332015 date "2021-08-01" @default.
• W3175332015 modified "2023-10-18" @default.
• W3175332015 title "Pneumonitis, appendicitis, and biliary obstruction during toripalimab treatment in a patient with extensive-stage small-cell lung cancer: a case report" @default.
• W3175332015 cites W1987103526 @default.
• W3175332015 cites W2048869426 @default.
• W3175332015 cites W2058264985 @default.
• W3175332015 cites W2073683299 @default.
• W3175332015 cites W2107150019 @default.
• W3175332015 cites W2108927999 @default.
• W3175332015 cites W2116607009 @default.
• W3175332015 cites W2145708352 @default.
• W3175332015 cites W2151177054 @default.
• W3175332015 cites W2152061559 @default.
• W3175332015 cites W2155599713 @default.
• W3175332015 cites W2166418266 @default.
• W3175332015 cites W2275606382 @default.
• W3175332015 cites W2292645700 @default.
• W3175332015 cites W2303102115 @default.
• W3175332015 cites W2527905628 @default.
• W3175332015 cites W2595075928 @default.
• W3175332015 cites W2625188669 @default.
• W3175332015 cites W2745840031 @default.
• W3175332015 cites W2753065806 @default.
• W3175332015 cites W2756648224 @default.
• W3175332015 cites W2782898385 @default.
• W3175332015 cites W2786816161 @default.
• W3175332015 cites W2788792303 @default.
• W3175332015 cites W2805482047 @default.
• W3175332015 cites W2810799290 @default.
• W3175332015 cites W2893960509 @default.
• W3175332015 cites W2904437471 @default.
• W3175332015 cites W2904888346 @default.
• W3175332015 cites W2923766093 @default.
• W3175332015 cites W2940759533 @default.
• W3175332015 cites W2943668434 @default.
• W3175332015 cites W2946109176 @default.
• W3175332015 cites W2965665272 @default.
• W3175332015 cites W2969253025 @default.
• W3175332015 cites W2974937072 @default.
• W3175332015 cites W2990621342 @default.
• W3175332015 cites W2995889981 @default.
• W3175332015 cites W2998514790 @default.
• W3175332015 cites W2998977965 @default.
• W3175332015 cites W3006075183 @default.
• W3175332015 cites W3011204026 @default.
• W3175332015 cites W3030178583 @default.
• W3175332015 cites W3044858467 @default.
• W3175332015 doi "https://doi.org/10.21037/apm-21-858" @default.
• W3175332015 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34488412" @default.
• W3175332015 hasPublicationYear "2021" @default.
• W3175332015 type Work @default.
• W3175332015 sameAs 3175332015 @default.
• W3175332015 citedByCount "2" @default.
• W3175332015 countsByYear W31753320152021 @default.
• W3175332015 countsByYear W31753320152023 @default.
• W3175332015 crossrefType "journal-article" @default.
• W3175332015 hasAuthorship W3175332015A5006012404 @default.
• W3175332015 hasAuthorship W3175332015A5040027560 @default.
• W3175332015 hasAuthorship W3175332015A5052267876 @default.
• W3175332015 hasAuthorship W3175332015A5056739581 @default.
• W3175332015 hasAuthorship W3175332015A5058579214 @default.
• W3175332015 hasAuthorship W3175332015A5065587658 @default.
• W3175332015 hasAuthorship W3175332015A5065992804 @default.
• W3175332015 hasAuthorship W3175332015A5074498404 @default.
• W3175332015 hasAuthorship W3175332015A5077741702 @default.
• W3175332015 hasAuthorship W3175332015A5082446850 @default.
• W3175332015 hasAuthorship W3175332015A5085659648 @default.
• W3175332015 hasBestOaLocation W31753320151 @default.
• W3175332015 hasConcept C126322002 @default.
• W3175332015 hasConcept C126838900 @default.
• W3175332015 hasConcept C141071460 @default.
• W3175332015 hasConcept C2776256026 @default.
• W3175332015 hasConcept C2777714996 @default.
• W3175332015 hasConcept C2779524853 @default.
• W3175332015 hasConcept C2780852908 @default.
• W3175332015 hasConcept C2780955771 @default.
• W3175332015 hasConcept C71924100 @default.
• W3175332015 hasConceptScore W3175332015C126322002 @default.
• W3175332015 hasConceptScore W3175332015C126838900 @default.
• W3175332015 hasConceptScore W3175332015C141071460 @default.
• W3175332015 hasConceptScore W3175332015C2776256026 @default.
• W3175332015 hasConceptScore W3175332015C2777714996 @default.
• W3175332015 hasConceptScore W3175332015C2779524853 @default.
• W3175332015 hasConceptScore W3175332015C2780852908 @default.
• W3175332015 hasConceptScore W3175332015C2780955771 @default.

• next